News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vanda Pharmaceuticals, Inc. (VNDA) to Announce Third Quarter 2013 Financial Results on November 7, 2013


10/22/2013 6:11:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WASHINGTON, Oct. 21, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the third quarter of 2013 on Thursday, November 7, 2013, before the market opens.

The Company will host a conference call at 10:00 AM ET on Thursday, November 7, 2013, during which Vanda management will discuss the financial results. To participate in the conference call, please dial 1-888-895-5271 (domestic) or 1-847-619-6547 (international) and use passcode 35919679.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, November 7, 2013, beginning at 12:00 PM ET and will be accessible until Thursday, November 14, 2013, at 5:00 PM ET. The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The passcode number is 35919679.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Chad Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@troutgroup.com

SOURCE Vanda Pharmaceuticals Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES